When was ImmuneOnco Biopharmaceuticals founded?

ImmuneOnco Biopharmaceuticals was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is ImmuneOnco Biopharmaceuticals located?

ImmuneOnco Biopharmaceuticals is headquartered in Shanghai, China.

Who is the current CEO of ImmuneOnco Biopharmaceuticals?

Tian Wenzhi of ImmuneOnco Biopharmaceuticals. They have also founded 1 company.

How many employees does ImmuneOnco Biopharmaceuticals have?

As of Apr 30, 2026, the latest employee count at ImmuneOnco Biopharmaceuticals is 15.

Is ImmuneOnco Biopharmaceuticals a funded company?

ImmuneOnco Biopharmaceuticals is a funded company, having raised a total of $146M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 2016.

When was the latest funding round of ImmuneOnco Biopharmaceuticals?

ImmuneOnco Biopharmaceuticals' latest funding was a $***** Series C round on Mar 25, 2021, with participation from 5 investors. Its primary sector is Immunotherapy. In China, the Immunotherapy sector has seen $209M in funding in 2026 to date.

Where does ImmuneOnco Biopharmaceuticals rank among its competitors?

ImmuneOnco Biopharmaceuticals ranks 216th amongst 3267 active competitors, of which 1129 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of ImmuneOnco Biopharmaceuticals?

ImmuneOnco Biopharmaceuticals' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

ImmuneOnco Biopharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

ImmuneOnco Biopharmaceuticals is a public company based in Shanghai (China), founded in 2015 by Tian Wenzhi. It operates as a Developer of therapeutic solutions for treating cancer. ImmuneOnco Biopharmaceuticals has raised $146M in funding from investors like Lilly Asia Ventures, Milestone and Shanghai Zhangjiang Technology Venture Capital. The company has 3267 active competitors, including 1129 funded and 770 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

ImmuneOnco Biopharmaceuticals is a developer of therapeutic solutions for treating cancer. The company has 8 candidates in the pipeline in the preclinical and discovery stages. The most advanced candidate is IMM01, an Fc-Fusion protein targeting CD47, indicated for Leukemia. The other advanced candidates are IMM02 and IMM03, both bi-functional proteins, indicated for solid tumors and lymphomas respectively.

Website: www.immuneonco.com
Email ID: *****@immuneonco.com
Phone Number: +86 **********

Key Metrics

Founded Year

2015

Location

Shanghai, China

Stage

Public

Total Funding

$146M in 7 rounds

Latest Funding Round

Series C, Mar 25, 2021, $*****

Investors

Lilly Asia Ventures & 10 more

Ranked

216^th among 3267 active competitors

Employee Count

15 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3037 more

Exit Details

Public

View ImmuneOnco Biopharmaceuticals' full profile

ImmuneOnco Biopharmaceuticals got listed on Sep 05, 2023.

Click here to take a look at ImmuneOnco Biopharmaceuticals's IPO in detail

ImmuneOnco Biopharmaceuticals has raised a total funding of $146M over 7 rounds. Its first funding round was on Apr 2016. Its latest funding round was a Series C round on Mar 25, 2021 for $*****. 5 investors participated in its latest round. ImmuneOnco Biopharmaceuticals has 10 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of ImmuneOnco Biopharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 25, 2021	1538466	Series C	6727176	1279040	1094281	5227426
Oct 12, 2020	2593119	Series B	9557180	2672643	2935065	LYFE Capital
Aug 27, 2020	9439409	Series A	9766759	5429540	4851482	9594601

Access funding benchmarks and valuations. Sign up today!

View details of ImmuneOnco Biopharmaceuticals's funding rounds and investors

The founders of ImmuneOnco Biopharmaceuticals is Tian Wenzhi. Tian Wenzhi is the CEO of ImmuneOnco Biopharmaceuticals.

Here are the details of ImmuneOnco Biopharmaceuticals' key team members:

Tian Wenzhi: Founder & CEO of ImmuneOnco Biopharmaceuticals.
Contact Info: 1 email address

View details of ImmuneOnco Biopharmaceuticals's Founder profiles and Board Members

ImmuneOnco Biopharmaceuticals' employee count trend

ImmuneOnco Biopharmaceuticals has 15 employees as of Apr 26. Here is ImmuneOnco Biopharmaceuticals's employee count trend over the years:

Employee count trend for ImmuneOnco Biopharmaceuticals

Uncover ImmuneOnco Biopharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ImmuneOnco Biopharmaceuticals include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of ImmuneOnco Biopharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
216th	ImmuneOnco Biopharmaceuticals 2015, Shanghai (China), Public	Developer of therapeutic solutions for treating cancer	$146M	Greater Bay Area Homeland Investments, LYFE Capital ... & 9 others	59/100